A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER-positive, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib or neratinib). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. During Stage 1, participants in each cohort will be randomly assigned to treatment arms. Participants in the control or experimental arms who experience unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator during Stage 1 will be given the option of receiving a different treatment combination during Stage 2, provided they meet eligibility criteria and a treatment arm is open for enrollment. No Stage 2 treatment is currently available.

Study Overview

• Status: Recruiting
• Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
• Intervention / Treatment: Drug: Giredestrant; Drug: Abemaciclib; Drug: Ipatasertib; Drug: Inavolisib; Drug: Ribociclib; Drug: Everolimus; Drug: Samuraciclib; Drug: Atezolizumab; Drug: PH FDC SC; Drug: Palbociclib

• Study Type: Interventional
• Enrollment (Estimated): 510
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Reference Study ID Number: CO42867 https://forpatients.roche.com/; Phone Number: 888-662-6728 (U.S. Only); Email: global-roche-genentech-trials@gene.com

Study Locations

• Australia
  • South Australia
    • Bedford Park, South Australia, Australia, 5042
      • Recruiting
      • Flinders Medical Centre
  • Victoria
    • Frankston, Victoria, Australia, 3199
      • Recruiting
      • Peninsula Health-Frankston Hospital
    • Melbourne, Victoria, Australia, 3000
      • Recruiting
      • Peter MacCallum Cancer Centre
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Recruiting
      • Linear Clinical Research Limited
• Israel
  • Jerusalem, Israel, 9112001
    • Recruiting
    • Hadassah Ein Karem Hospital
  • Petach Tikva, Israel, 4941492
    • Recruiting
    • Rabin MC; Davidof Center - Oncology Institute
  • Ramat Gan, Israel, 5211401
    • Recruiting
    • The Chaim Sheba Medical Center
  • Tel Aviv, Israel, 6423906
    • Recruiting
    • Tel Aviv Sourasky Medical Center; Movement Disorder
• Korea, Republic of
  • Goyang-si, Korea, Republic of, 10408
    • Recruiting
    • National Cancer Center
  • Seoul, Korea, Republic of, 03080
    • Recruiting
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 05505
    • Recruiting
    • Asan Medical Center
  • Seoul, Korea, Republic of, 06351
    • Recruiting
    • Samsung Medical Center
  • Seoul, Korea, Republic of, 03722
    • Recruiting
    • Severance Hospital
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitario Vall d Hebron
  • Madrid, Spain, 28034
    • Recruiting
    • Hospital Universitario Ramón y Cajal
  • Madrid, Spain, 28050
    • Recruiting
    • Centro Integral Oncológico Clara Campal Ensayos Clínicos START
  • Valencia, Spain, 46010
    • Recruiting
    • Hospital Clinico Universitario de Valencia; Servicio de Anatomia Patologica
• United States
  • California
    • Duarte, California, United States, 91010
      • Completed
      • City of Hope
    • San Francisco, California, United States, 94143
      • Recruiting
      • University of California, San Francisco (UCSF)
    • Santa Monica, California, United States, 90404
      • Recruiting
      • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    • Stanford, California, United States, 94305
      • Recruiting
      • Stanford Cancer Institute (SCI)
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Recruiting
      • Massachusetts General Hospital
  • New Jersey
    • Freehold, New Jersey, United States, 07728
      • Recruiting
      • Regional Cancer Care Associates LLC (RCCA) - Freehold Location
    • Howell, New Jersey, United States, 07731
      • Recruiting
      • Regional Cancer Care Associates LLC ? Howell Division
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Recruiting
      • Levine Cancer Institute
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Recruiting
      • Thomas Jefferson University Hospital;Medical Oncology
    • Pittsburgh, Pennsylvania, United States, 15219
      • Recruiting
      • University of Pittsburgh Cancer Institute
  • Tennessee
    • Germantown, Tennessee, United States, 38138
      • Recruiting
      • West Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Inclusion Criteria for Cohort 1 (Stage 1 [and Stage 2, only where indicated]):

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Documented estrogen receptor-positive (ER+) tumor
• Patients for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
• Radiologic/objective evidence of recurrence or progression after the most recent systemic therapy for breast cancer
• Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease (note: at least one line of therapy must have contained a CDK4/6i administered for a minimum of 8 weeks prior to disease progression.)
• Postmenopausal status for women
• Life expectancy ≥3 months
• Availability of a representative tumor specimen that is suitable for biomarker evaluation via central testing
• Prior fulvestrant therapy is allowed
• Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1
• Stages 1 and 2: Adequate hematologic and end-organ function
• Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation

Inclusion Criteria for Cohort 2 (Stage 1 [and Stage 2, only where indicated]):

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection
• ER-positive, HER2-positive breast cancer
• Postmenopausal status for women
• Life expectancy ≥3 months
• Willingness to have a representative tumor specimen that is suitable for biomarker evaluation via central testing submitted, if available
• Prior endocrine therapy in the advanced setting allowed, including fulvestrant if given more than 28 days prior to randomization, but excluding other selective estrogen receptor degraders (SERDs)
• Stages 1 and 2: Measurable disease (at least one target lesion) according to RECIST v1.1
• Stages 1 and 2: Baseline left ventricular ejection fraction (LVEF) ≥50% as measured by ECHO or MUGA scans
• Stages 1 and 2: Adequate hematologic and end-organ function
• Stages 1 and 2: Stable anticoagulant regimen for patients receiving therapeutic anticoagulation

Inclusion Criteria for Cohorts 1 and 2 (Stage 2):

• Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator, provided that a Stage 2 slot is available and patient meets eligibility criteria for Stage 2
• Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 because of unacceptable toxicity to drugs, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator

Exclusion Criteria:

General Exclusion Criteria for all Treatment Arms in Stage 1, Cohorts 1 and 2 (unless only applicable to one cohort, as indicated):

• Prior treatment with any of the protocol-specified study treatments
• Treatment with investigational therapy within 28 days prior to initiation of study treatment
• Systemic treatment for breast cancer within 2 weeks of Cycle 1, Day 1 or 5 half-lives of the drug prior to Cycle 1, Day 1
• Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
• Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 or better, with the exception of alopecia of any grade and Grade ≤2 peripheral neuropathy
• Eligible only for the control arm
• Prior allogeneic stem cell or solid organ transplantation
• Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study
• History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
• Uncontrolled tumor-related pain
• Uncontrolled or symptomatic hypercalcemia
• Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
• History of leptomeningeal disease
• Active tuberculosis
• Severe infection within 4 weeks prior to initiation of study treatment
• Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
• Active cardiac disease or history of cardiac dysfunction
• Positive HIV test at screening or at any time prior to screening
• Active Hepatitis B or Hepatitis C virus infection
• Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery, including gastric resection, potentially affecting enteral absorption
• Known allergy or hypersensitivity to any of the study drugs or any of their excipients applicable to one cohort, as indicated):
• Cohort 1 only: Known HER2-positive breast cancer
• Cohort 1 only: Concurrent hormone replacement therapy
• Cohort 1 only: Prior treatment with cytotoxic chemotherapy for metastatic breast cancer (with the exception of single agent capecitabine, which will count as a single line of therapy)
• Cohort 2 only: Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
• Cohort 2 only: Current chronic daily treatment (continuous for >3 months) with corticosteroids (dose of 10 mg/day methylprednisolone equivalent), excluding inhaled steroids

Additional Exclusion Criteria for Giredestrant + Abemaciclib Arm and Giredestrant + Abemaciclib + Atezolizumab Arm (Cohort 1, Stage 1):

• Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy
• History of major surgical resection involving the stomach or small bowel, or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea
• History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest

Additional Exclusion Criteria for Giredestrant + Ipatasertib Arm (Cohort 1, Stage 1):

• Prior treatment with an Akt inhibitor
• Inability to swallow medication or malabsorption condition that would alter the absorption of orally administered medications
• Grade ≥2 uncontrolled or untreated hypercholesterolemia or hypertriglyceremia
• History of Type 1 or Type 2 diabetes mellitus requiring insulin
• History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion

Additional Exclusion Criteria for Giredestrant + Inavolisib Arm (Cohort 1, Stage 1):

• Prior treatment with any PI3K, Akt, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K/Akt/mTOR pathway
• Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
• Fasting glucose ≥126 mg/dL or ≥7.0 mmol/L and HbA1c ≥5.7%
• Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition
• Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
• Symptomatic active lung disease, including pneumonitis
• Inability to confirm biomarker eligibility based on valid results from either central testing of blood or local testing of blood or tumor tissue that documents one of the protocol-defined PIK3CA mutations

Additional Exclusion Criteria for Giredestrant + Ribociclib Arm (Cohort 1, Stage 1):

• Currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting trial treatment
• Impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments

Additional Exclusion Criteria for Giredestrant + Samuraciclib Arm (Cohort 1, Stage 1):

• Prior treatment with mTOR inhibitor
• Receipt of systemic corticosteroids (at a dose >10 mg prednisone/day or equivalent) within 14 days before the first dose of samuraciclib
• Active bleeding diatheses
• History of hemolytic anemia or marrow aplasia
• Receipt of a live-virus vaccination within 28 days or less of planned treatment start

Additional Exclusion Criteria for Giredestrant + Atezolizumab-Containing Arms (Cohort 1, Stage 1):

• Active or history of autoimmune disease or immune deficiency
• Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
• Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
• Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
• History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
• Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• Pregnant or breastfeeding, or intending to become pregnant during study treatment or within 5 months for atezolizumab

Additional Exclusion Criteria for Giredestrant + PH FDC SC + Abemaciclib Arm (Cohort 2, Stage 1):

• Interstitial lung disease or severe dyspnea
• History of major surgical resection involving the stomach or small bowel, preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, or a condition that may significantly alter the absorption of the oral trial treatments
• History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest

Additional Exclusion Criteria for Giredestrant + PH FDC SC + Palbociclib Arm (Cohort 2, Stage 1):

• History of major surgical resection involving the stomach or small bowel, preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, or a condition that may significantly alter the absorption of the oral trial treatments
• Interstitial lung disease or severe dyspnea

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cohort 1: Giredestrant Monotherapy	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171
Experimental: Cohort 1: Giredestrant + Abemaciclib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Abemaciclib; 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: Verzenio™
Experimental: Cohort 1: Giredestrant + Ipatasertib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Ipatasertib; 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression; Other Names: GDC-0068; RG7440; RO5532961
Experimental: Cohort 1: Giredestrant + Inavolisib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Inavolisib; 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression; Other Names: GDC-0077; RG6114; RO7113755
Experimental: Cohort 1: Giredestrant + Ribociclib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Ribociclib; 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression; Other Names: Kisqali®
Experimental: Cohort 1: Giredestrant + Everolimus	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Everolimus; 10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression; Other Names: Afinitor®
Experimental: Cohort 1: Giredestrant + Samuraciclib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Samuraciclib; 360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression; Other Names: ICEC0942; CT7001
Experimental: Cohort 1: Giredestrant + Atezolizumab	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Atezolizumab; 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.; Other Names: RO5541267; Tecentriq®; RG7446
Experimental: Cohort 1: Giredestrant + Abemaciclib + Atezolizumab	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Abemaciclib; 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: Verzenio™; Drug: Atezolizumab; 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.; Other Names: RO5541267; Tecentriq®; RG7446
Active Comparator: Cohort 2: Giredestrant + PH FDC SC	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: PH FDC SC; On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.; Other Names: PHESGO™; RG6264; RO7198574; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Experimental: Cohort 2: Giredestrant + PH FDC SC + Abemaciclib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: Abemaciclib; 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: Verzenio™; Drug: PH FDC SC; On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.; Other Names: PHESGO™; RG6264; RO7198574; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Experimental: Cohort 2: Giredestrant + PH FDC SC + Palbociclib	Drug: Giredestrant; 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression; Other Names: GDC-9545; RO7197597; RG6171; Drug: PH FDC SC; On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.; Other Names: PHESGO™; RG6264; RO7198574; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Drug: Palbociclib; 125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression; Other Names: Ibrance®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)	From Baseline until disease progression (up to 6 years)
Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)	From Baseline until 30 days after the last dose of study drug (up to 6 years)
Plasma Concentration of Giredestrant at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 8, and 16 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)
Plasma Concentration of Abemaciclib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)
Plasma Concentration of Ipatasertib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days)
Plasma Concentration of Inavolisib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days)
Plasma Concentration of Ribociclib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycle 2 (each cycle is 28 days)
Blood Concentration of Everolimus at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycle 2 (each cycle is 28 days)
Plasma Concentration of Samuraciclib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 8, and 16 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)
Serum Concentration of Pertuzumab in PH FDC SC Treatment Arms at Specified Timepoints	Day 1 of Cycles 1 and 4 (each cycle is 21 days), and at treatment discontinuation visit (within 30 days after last dose)
Serum Concentration of Trastuzumab in PH FDC SC Treatment Arms at Specified Timepoints	Day 1 of Cycles 1 and 4 (each cycle is 21 days), and at treatment discontinuation visit (within 30 days after last dose)
Plasma Concentration of Palbociclib at Specified Timepoints	Days 1 and 15 of Cycle 1; Day 1 of Cycles 2 and 3 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)
Serum Concentration of Atezolizumab at Specified Timepoints	Days 1 of Cycles 1, 2, 3, 4, 8, 12, and 16 (each cycle is 28 days), and at treatment discontinuation visit (within 30 days after last dose)

Secondary Outcome Measures

Outcome Measure	Time Frame
Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1	From randomization to the date of the first recorded occurrence of disease progression or death from any cause, whichever occurs first (up to 6 years)
Disease Control Rate, Defined as the Percentage of Participants with Stable Disease for ≥12 Weeks or a Complete or Partial Response, as Determined by the Investigator According to RECIST v1.1	From Baseline until disease progression (up to 6 years)
Clinical Benefit Rate, Defined as the Percentage of Participants with Stable Disease for ≥24 Weeks or with Confirmed Complete or Partial Response, as Determined by the Investigator According to RECIST v1.1	From Baseline until disease progression (up to 6 years)
Overall Survival	From randomization to death from any cause (up to 6 years)
Duration of Response, as Determined by the Investigator According to RECIST v1.1	From first occurrence of a document objective response to the first date of recorded disease progression or death from any cause, whichever occurs first (up to 6 years)

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Actual): June 20, 2021
• Primary Completion (Estimated): April 30, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: March 15, 2021
• First Submitted That Met QC Criteria: March 16, 2021
• First Posted (Actual): March 17, 2021

Study Record Updates

• Last Update Posted (Actual): April 4, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Immune Checkpoint Inhibitors; Phosphoinositide-3 Kinase Inhibitors; MTOR Inhibitors; Trastuzumab; Palbociclib; Everolimus; Atezolizumab; Pertuzumab; Ipatasertib; Inavolisib
• Other Study ID Numbers: CO42867; 2020-004889-19 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No